CIBUS INC
CBUSNASDAQ🏆 #2937 by market capEarnings Aug 13US Equity
$1.90▼ $0.01 (−0.52%)
🌙 After hours$1.90▲ 0.00%Regular close · extended-hours price shown1h—
24h▼ 0.5%
7d—
14d—
30d—
1y—
🏦Market Cap
$145M
Small Cap
📈Revenue Growth (YoY)
-9.8%
Declining
📊Gross Margin
100.0%
High
💵FCF Margin
—
⚖️P/S Ratio
34.7x
Expensive
Otter Score
45
Weak
No chart data available for CBUS.
Trading Snapshot
- Day Range
- $1.87 – $1.91
- 52-Week Range
- $1.09 – $4.19
- Volume
- $2.80B
- Avg Volume
- $2.10B
- Shares Outstanding
- 76.3M
- Next Earnings
- Sep 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 34.7x
- EPS (TTM)
- $-1.97
- Dividend Yield
- —
Why Investors Own CBUS
- ✓High-growth profile — revenue up +2.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$4M▲ +7.5% YoY
Gross Margin (TTM)
69.5%▼ −0.2% YoY
Operating Income (TTM)
$443,958▲ +7.5% YoY
Free Cash Flow (TTM)
$149,199▲ +7.5% YoY
About CIBUS INC
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Ratings
ⓘConsensus
Buy
9 analysts
Strong Buy2
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Aug 2026
